Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.

Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, Shei RJ, Adewale AT, Lenzie AR, Fernandez-Petty CM, Zheng H, Palermo JH, Cho DY, Woodworth BA, Yonker LM, Hurley BP, Rowe SM, Tearney GJ.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav3505. doi: 10.1126/scitranslmed.aav3505.

PMID:
31391319
2.

Macrocyclisation and functionalisation of unprotected peptides via divinyltriazine cysteine stapling.

Robertson NS, Walsh SJ, Fowler E, Yoshida M, Rowe SM, Wu Y, Sore HF, Parker JS, Spring DR.

Chem Commun (Camb). 2019 Aug 7;55(64):9499-9502. doi: 10.1039/c9cc05042f.

PMID:
31328756
3.
4.

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM.

ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr.

5.

Use of a sanitary sheath at artificial insemination by nonprofessional technicians does not markedly improve pregnancy rates to artificial insemination in pasture-based dairy cows.

Hosie J, Rowe SM, Morton JM, Tranter WP, Cavalieri J.

J Dairy Sci. 2019 Jun;102(6):5588-5598. doi: 10.3168/jds.2018-16082. Epub 2019 Apr 17.

PMID:
31005323
6.

A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.

Fernandez-Petty CM, Hughes GW, Bowers HL, Watson JD, Rosen BH, Townsend SM, Santos C, Ridley CE, Chu KK, Birket SE, Li Y, Leung HM, Mazur M, Garcia BA, Evans TIA, Libby EF, Hathorne H, Hanes J, Tearney GJ, Clancy JP, Engelhardt JF, Swords WE, Thornton DJ, Wiesmann WP, Baker SM, Rowe SM.

JCI Insight. 2019 Apr 18;4(8). pii: 125954. doi: 10.1172/jci.insight.125954. eCollection 2019 Apr 18.

7.

Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.

Cho DY, Skinner D, Mackey C, Lampkin HB, Elder JB, Lim DJ, Zhang S, McCormick J, Tearney GJ, Rowe SM, Woodworth BA.

Int Forum Allergy Rhinol. 2019 Jun;9(6):629-637. doi: 10.1002/alr.22290. Epub 2019 Jan 18.

PMID:
30657641
8.

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809.

Doiron JE, Le CA, Ody BK, Brace JB, Post SJ, Thacker NL, Hill HM, Breton GW, Mulder MJ, Chang S, Bridges TM, Tang L, Wang W, Rowe SM, Aller SG, Turlington M.

Chemistry. 2019 Mar 7;25(14):3662-3674. doi: 10.1002/chem.201805919. Epub 2019 Feb 11.

PMID:
30650214
9.

Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.

Lin VY, Fain MD, Jackson PL, Berryhill TF, Wilson LS, Mazur M, Barnes SJ, Blalock JE, Raju SV, Rowe SM.

Am J Respir Cell Mol Biol. 2019 Aug;61(2):162-173. doi: 10.1165/rcmb.2017-0432OC.

PMID:
30576219
10.

Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

Donaldson SH, Laube BL, Corcoran TE, Bhambhvani P, Zeman K, Ceppe A, Zeitlin PL, Mogayzel PJ Jr, Boyle M, Locke LW, Myerburg MM, Pilewski JM, Flanagan B, Rowe SM, Bennett WD.

JCI Insight. 2018 Dec 20;3(24). pii: 122695. doi: 10.1172/jci.insight.122695.

11.

Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice.

Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, Hill DB, Kissner WJ, Markovetz MR, Grove Villalon DE, Voss ME, Tearney GJ, Carroll KS, Shi Y, Schwarz MI, Thelin WR, Rowe SM, Yang IV, Evans CM, Schwartz DA.

Nat Commun. 2018 Dec 18;9(1):5363. doi: 10.1038/s41467-018-07768-9.

12.

Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis.

Oates GR, Stepanikova I, Rowe SM, Gamble S, Gutierrez HH, Harris WT.

Respir Care. 2019 Feb;64(2):176-181. doi: 10.4187/respcare.06436. Epub 2018 Dec 11.

PMID:
30538158
13.

Colocolonic intussusception in an adult cystic fibrosis patient.

Timothy Adewale A, Rowe SM, Solomon GM.

J Cyst Fibros. 2019 Mar;18(2):e11-e13. doi: 10.1016/j.jcf.2018.11.013. Epub 2018 Nov 29.

PMID:
30503033
14.

Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.

McCormick J, Cho DY, Lampkin B, Richman J, Hathorne H, Rowe SM, Woodworth BA.

Int Forum Allergy Rhinol. 2019 Mar;9(3):292-297. doi: 10.1002/alr.22251. Epub 2018 Nov 24.

PMID:
30472785
15.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19.

16.

Functional Anatomic Imaging of the Airway Surface.

Shei RJ, Peabody JE, Rowe SM.

Ann Am Thorac Soc. 2018 Nov;15(Suppl 3):S177-S183. doi: 10.1513/AnnalsATS.201806-407AW.

PMID:
30431349
17.

Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats.

Plyler ZE, Birket SE, Schultz BD, Hong JS, Rowe SM, Petty CF, Crowley MR, Crossman DK, Schoeb TR, Sorscher EJ.

Mech Dev. 2019 Feb;155:15-26. doi: 10.1016/j.mod.2018.10.002. Epub 2018 Nov 2.

PMID:
30391480
18.

Effect of equine chorionic gonadotropin on reproductive performance in a dairy herd in Northern Queensland, Australia.

Rowe SM, Pryor L, Tranter WP, Hosie J, Cavalieri J.

Theriogenology. 2019 Feb;125:30-36. doi: 10.1016/j.theriogenology.2018.10.016. Epub 2018 Oct 18.

PMID:
30388468
19.

Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema.

Aggarwal S, Ahmad I, Lam A, Carlisle MA, Li C, Wells JM, Raju SV, Athar M, Rowe SM, Dransfield MT, Matalon S.

JCI Insight. 2018 Nov 2;3(21). pii: 120694. doi: 10.1172/jci.insight.120694.

20.

The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.

Shei RJ, Peabody JE, Kaza N, Rowe SM.

Curr Opin Pharmacol. 2018 Dec;43:152-165. doi: 10.1016/j.coph.2018.09.007. Epub 2018 Oct 16. Review.

PMID:
30340955
21.

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.

22.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

23.

Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis.

Brand JD, Lazrak A, Trombley JE, Shei RJ, Adewale AT, Tipper JL, Yu Z, Ashtekar AR, Rowe SM, Matalon S, Harrod KS.

JCI Insight. 2018 Oct 18;3(20). pii: 123467. doi: 10.1172/jci.insight.123467.

24.

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Solomon GM, Bronsveld I, Hayes K, Wilschanski M, Melotti P, Rowe SM, Sermet-Gaudelus I.

J Vis Exp. 2018 Sep 13;(139). doi: 10.3791/57006.

PMID:
30272672
25.

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study.

Teerapuncharoen K, Wells JM, Raju SV, Raraigh KS, Atalar Aksit M, Cutting GR, Rasmussen L, Nath PH, Bhatt SP, Solomon GM, Dransfield MT, Rowe SM.

Ann Am Thorac Soc. 2019 Jan;16(1):150-153. doi: 10.1513/AnnalsATS.201805-325RL. No abstract available.

PMID:
30230364
26.

A revised airway epithelial hierarchy includes CFTR-expressing ionocytes.

Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, Yuan F, Chen S, Leung HM, Villoria J, Rogel N, Burgin G, Tsankov AM, Waghray A, Slyper M, Waldman J, Nguyen L, Dionne D, Rozenblatt-Rosen O, Tata PR, Mou H, Shivaraju M, Bihler H, Mense M, Tearney GJ, Rowe SM, Engelhardt JF, Regev A, Rajagopal J.

Nature. 2018 Aug;560(7718):319-324. doi: 10.1038/s41586-018-0393-7. Epub 2018 Aug 1.

27.

EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.

Elborn JS, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM.

Contemp Clin Trials. 2018 Sep;72:86-94. doi: 10.1016/j.cct.2018.07.014. Epub 2018 Jul 26.

28.

An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy.

Duncan GA, Kim N, Colon-Cortes Y, Rodriguez J, Mazur M, Birket SE, Rowe SM, West NE, Livraghi-Butrico A, Boucher RC, Hanes J, Aslanidi G, Suk JS.

Mol Ther Methods Clin Dev. 2018 Mar 22;9:296-304. doi: 10.1016/j.omtm.2018.03.006. eCollection 2018 Jun 15.

29.

Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations.

Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1099-1102. doi: 10.1164/rccm.201802-0338LE. No abstract available.

PMID:
30011228
30.

Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats.

McCormick LL, Phillips SE, Kaza N, Tang LP, Rasmussen L, Byzek SA, Raju SV, Rowe SM.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):672-674. doi: 10.1164/rccm.201805-0827LE. No abstract available.

PMID:
29979606
31.

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM; GOALe(2) Investigators.

J Cyst Fibros. 2019 Jan;18(1):102-109. doi: 10.1016/j.jcf.2018.04.004. Epub 2018 Apr 21.

PMID:
29685811
32.

Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Sagel SD, Donaldson SH, Rowe SM, Rosenfeld M.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):526-528. doi: 10.1164/rccm.201802-0243LE. No abstract available.

PMID:
29614238
33.

Seeing cilia: imaging modalities for ciliary motion and clinical connections.

Peabody JE, Shei RJ, Bermingham BM, Phillips SE, Turner B, Rowe SM, Solomon GM.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L909-L921. doi: 10.1152/ajplung.00556.2017. Epub 2018 Mar 1. Review.

34.

Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.

Guimbellot JS, Acosta EP, Rowe SM.

Pediatr Pulmonol. 2018 May;53(5):E6-E8. doi: 10.1002/ppul.23971. Epub 2018 Feb 28.

35.

Effect of pre-milking teat disinfection on clinical mastitis incidence in a dairy herd in Northern Queensland, Australia.

Rowe SM, Tranter WP, Laven RA.

Aust Vet J. 2018 Mar;96(3):69-75. doi: 10.1111/avj.12674.

PMID:
29479684
36.

Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.

Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, Antony VB, Rowe SM, Solomon GM.

BMC Pulm Med. 2018 Feb 14;18(1):35. doi: 10.1186/s12890-018-0594-8.

37.

Sinus Microanatomy and Microbiota in a Rabbit Model of Rhinosinusitis.

Cho DY, Mackey C, Van Der Pol WJ, Skinner D, Morrow CD, Schoeb TR, Rowe SM, Swords WE, Tearney GJ, Woodworth BA.

Front Cell Infect Microbiol. 2018 Jan 12;7:540. doi: 10.3389/fcimb.2017.00540. eCollection 2017.

38.

Not simply the lesser of two evils.

Raju SV, Rowe SM.

Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1;314(2):L236-L238. doi: 10.1152/ajplung.00534.2017. Epub 2017 Dec 20. No abstract available.

39.

Development of an airway mucus defect in the cystic fibrosis rat.

Birket SE, Davis JM, Fernandez CM, Tuggle KL, Oden AM, Chu KK, Tearney GJ, Fanucchi MV, Sorscher EJ, Rowe SM.

JCI Insight. 2018 Jan 11;3(1). pii: 97199. doi: 10.1172/jci.insight.97199. eCollection 2018 Jan 11.

40.

Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.

Heltshe SL, Rowe SM, Skalland M, Baines A, Jain M; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1483-1486. doi: 10.1164/rccm.201710-2046LE. No abstract available.

41.

MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, Rowe SM, Harris WT.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):632-643. doi: 10.1164/rccm.201704-0732OC.

42.

Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B.

Cho DY, Hoffman KJ, Gill GS, Lim DJ, Skinner D, Mackey C, Rowe SM, Woodworth BA.

World J Otorhinolaryngol Head Neck Surg. 2017 Mar 7;3(1):2-8. doi: 10.1016/j.wjorl.2017.01.002. eCollection 2017 Mar.

43.

Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat.

Stalvey MS, Havasi V, Tuggle KL, Wang D, Birket S, Rowe SM, Sorscher EJ.

PLoS One. 2017 Nov 30;12(11):e0188497. doi: 10.1371/journal.pone.0188497. eCollection 2017.

44.

The therapeutic potential of CFTR modulators for COPD and other airway diseases.

Solomon GM, Fu L, Rowe SM, Collawn JF.

Curr Opin Pharmacol. 2017 Jun;34:132-139. doi: 10.1016/j.coph.2017.09.013. Epub 2017 Nov 10. Review.

45.

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.

N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3.

46.

Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia.

Krick S, Baumlin N, Aller SP, Aguiar C, Grabner A, Sailland J, Mendes E, Schmid A, Qi L, David NV, Geraghty P, King G, Birket SE, Rowe SM, Faul C, Salathe M.

Sci Rep. 2017 Oct 30;7(1):14388. doi: 10.1038/s41598-017-14811-0.

47.

Use of ferrets for electrophysiologic monitoring of ion transport.

Kaza N, Raju SV, Cadillac JM, Trombley JA, Rasmussen L, Tang L, Dohm E, Harrod KS, Rowe SM.

PLoS One. 2017 Oct 27;12(10):e0186984. doi: 10.1371/journal.pone.0186984. eCollection 2017.

48.

Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.

Raju SV, Rasmussen L, Sloane PA, Tang LP, Libby EF, Rowe SM.

Respir Res. 2017 Sep 18;18(1):173. doi: 10.1186/s12931-017-0656-0.

49.

Toward inclusive therapy with CFTR modulators: Progress and challenges.

Guimbellot J, Sharma J, Rowe SM.

Pediatr Pulmonol. 2017 Nov;52(S48):S4-S14. doi: 10.1002/ppul.23773. Epub 2017 Sep 7. Review.

50.

Assessment of acquired mucociliary clearance defects using micro-optical coherence tomography.

Tipirneni KE, Grayson JW, Zhang S, Cho DY, Skinner DF, Lim DJ, Mackey C, Tearney GJ, Rowe SM, Woodworth BA.

Int Forum Allergy Rhinol. 2017 Sep;7(9):920-925. doi: 10.1002/alr.21975. Epub 2017 Jun 28.

Supplemental Content

Support Center